SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving social volume. Some users are pointing out the project has been live on Solana for over a year and has a locked and burned LP. Others suggest the recent increase in social volume is due to only one or two accounts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate upcoming earnings, with community members highlighting the potential impact of QNX technology and key partnerships with companies like AMD and Nvidia. Bullish sentiment is fueled by expectations of strong financial performance and the possibility of future share buybacks. Some investors suggest BlackBerry is undervalued, drawing comparisons to AMD's earlier growth trajectory.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its drug sonelokimab in treating hidradenitis suppurativa, leading to raised price targets and speculation about its potential as a best-in-class treatment. The community is actively discussing the implications of this data, especially compared to competitors, and the possibility of a future buyout. Some investors believe MLTX is thoroughly de-risked.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as users discuss its potential as the next BTC.X, highlighting its capped supply and upcoming halving event. Community members are also excited about its multi-chain availability and integration within the ICP.X ecosystem.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The U.S. Dollar Index ($UUP) is trending as traders weigh the potential impact of a strong dollar against expectations for future Federal Reserve policy. Community members are analyzing technical indicators and potential breakout levels, while also considering the impact of tariffs and trade deals. Discussions revolve around the dollar's relationship with other asset classes like gold and equities.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to discussions around its partnerships and deployments in the Middle East and Southeast Asia, including Singapore and Abu Dhabi. The community is debating whether WeRide is undervalued compared to competitors like Pony.ai, despite its revenue growth and expansion. Recent news of UBS initiating coverage with a buy rating and the upcoming Grab earnings call are also fueling interest.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

VIXY is trending as traders discuss potential market volatility driven by factors like geopolitical tensions (Middle East), tariff concerns, and economic data. Community members are actively analyzing yearly charts and technical patterns, with some anticipating a volatility spike and hedging their portfolios, while others point to the potential for market manipulation.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

$LENNY.X is trending as the 'OG face of the internet' aims to build a strong community and 'Lenny Cult'. Social media mentions highlight conviction and relentless grinding towards solidifying the project's place in meme history, with community members encouraging others to 'get Lennyfied'.

Pump.fun

Pump.fun is trending as users discuss potential gains and trading strategies, with some highlighting its connection to Solana and other cryptocurrencies. Community members are actively debating entry points, expressing both bullish and bearish sentiments, and mentioning the potential for significant price movement. The platform's buyback program and the involvement of key community members are also being closely watched.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas is trending as the community discusses its recent listing on MEXC and potential for significant growth. Comparisons to other tokens like PENGU are circulating, with many highlighting its strong fundamentals and NFT presence. Holders are expressing bullish sentiment, anticipating a potential breakout and encouraging others to research the token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

Retail traders kept a cautious stance on Summit Therapeutics on Tuesday after Barclays initiated coverage of the biotech with an ‘Underweight’ rating and a $13 price target.&nbsp;The stock fell 4.3% to $18.12 on Tuesday and slipped another 0.4% after hours.Barclays flagged a long regulatory path, stiff competition in lung cancer, and a rival backed by a major pharma partner as key risks.The brokerage said it still sees a “high likelihood” of approval for ivonescimab, Summit’s experimental bispecific antibody, but its models suggest only modest improvements over the current standard of care.&nbsp;The note contrasted with&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/summit-therapeutics-gets-40-dollar-price-target-from-guggenheim/chwdQXARdpT">Guggenheim’s initiation</a> earlier this month at ‘Buy’ with a $40 price target, which argued the company’s late-stage trials could offer multi-fold upside if successful.The cautious call comes just days after Summit presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-traders-flock-to-summit-therapeutics-after-new-cancer-drug-data-shows-survival-gains/chwW19jRdqH">new follow-up data from its Phase III HARMONi trial</a> at the World Conference on Lung Cancer in Barcelona. Patients with advanced non-small cell lung cancer on ivonescimab plus chemotherapy lived a median of 16.8 months versus 14 months on chemo alone, with hazard ratios pointing to survival benefits across Western and Asian cohorts.&nbsp;Earlier results showed the study met its main goal, cutting the risk of progression or death by 48% compared with chemotherapy alone.Ivonescimab, licensed from China’s Akeso and already approved there as SMT112, has been tested in more than 2,800 patients worldwide and carries a U.S. FDA Fast Track designation.&nbsp;Summit is running additional late-stage trials, HARMONi-3 and HARMONi-7, comparing ivonescimab against Merck’s blockbuster PD-1 drug Keytruda in first-line lung cancer, with readouts expected between 2027 and 2028.On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.One user remarked that they would only consider buying Summit Therapeutics if it returned to penny-stock levels, calling it “another one added to the biotech graveyard.”<stembedurl>https://stocktwits.com/Jahlisgo/message/628908644</stembedurl>Another user said they were holding their shares following the updated brokerage reports, waiting for what they described as a future payday.<stembedurl>https://stocktwits.com/Reesh/message/628891775</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’

Barclays set a $13 price target, citing a long regulatory path and stiff competition in lung cancer.

Equity

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Retail traders turned their attention to Summit Therapeutics late Sunday after the company released new follow-up data from its Phase III HARMONi trial. The study is testing ivonescimab, an experimental cancer drug, together with chemotherapy in patients with advanced non-small cell lung cancer.The trial focused on people whose tumors carried Estimated Glomerular Filtration Rate (EGFR) mutations and who had already failed a third-generation EGFR therapy. In this group, past attempts with PD-1 drugs had not delivered survival gains.In fresh results presented at the World Conference on Lung Cancer in Barcelona, patients on ivonescimab plus chemotherapy lived longer on average than those on chemotherapy alone.&nbsp;The overall survival hazard ratio&nbsp;was 0.78,&nbsp;indicating an improvement from the earlier analysis. Median survival was 16.8 months with the drug compared to 14.0 months with chemotherapy.Among Western patients,&nbsp;the median overall survival&nbsp;was 17 months with ivonescimab versus 14 months for the placebo. In North America specifically, median overall survival had not yet been reached in the ivonescimab arm compared with 14 months on chemotherapy alone.&nbsp;Median survival in Asian patients was 16.7 months for ivonescimab versus 14 months for chemotherapy.The primary analysis, conducted in April, had shown a positive trend in overall survival but did not meet statistical significance. The company noted that&nbsp;the median follow-up for Western patients was shorter than their median overall survival at that time.Earlier results had already&nbsp;demonstrated that the trial met its main goal. Patients on ivonescimab plus chemotherapy were 48% less likely to see their cancer worsen or to die compared with those on chemotherapy alone.The treatment also produced better responses: 45% of patients saw their tumors shrink versus 34% on chemotherapy, and those responses lasted longer, with a median of 7.6 months compared with 4.2 months.Safety data showed the combination was generally manageable and consistent with prior studies.&nbsp;Grade 3 or higher treatment-related adverse events occurred in 50% of ivonescimab patients versus 42.2% in the chemotherapy arm. Discontinuations due to adverse events were 7.3% versus 5%, and treatment-related deaths were reported in 1.8% and 2.3% of patients, respectively. The most common events were anemia and reduced blood counts, with less than 1% of ivonescimab patients experiencing severe hemorrhage.Ivonescimab, also known as SMT112 outside China, is a first-in-class bispecific antibody targeting both PD-1 and Vascular Endothelial Growth Factor (VEGF).&nbsp;It was engineered by China’s Akeso and has been tested in more than 2,800 patients globally. The drug is already approved in China and has&nbsp;a U.S. FDA Fast Track designation in the HARMONi trial setting.On Stocktwits, retail sentiment for Summit was ‘extremely bullish’ amid ‘extremely high’ message volume.One retail user said that long-term investors in Summit had grown used to the stock falling even on positive news, but pointed out shares are still up nearly 700% over the past five years.<stembedurl>https://stocktwits.com/EB2224/message/627780145</stembedurl>Another user noted that while the day had been volatile, “the markets don’t lie” and suggested Summit CEO Robert Duggan might have more to reveal, adding that he has a reputation for frustrating short sellers. The user speculated the stock could hit $30 by the end of the day.<stembedurl>https://stocktwits.com/BooEmmy/message/627780010</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 45.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Summit’s stock (SMMT) has risen 45.6% so far in 2025. (Photo credit: Getty Images)

Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains

The updated Phase III HARMONi trial showed Western patients on ivonescimab lived a median 17 months versus 14 months on chemotherapy.

Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target.The price target represents a 70% upside from the stock’s closing price on Wednesday. SMMT stock has had a good run over the past year, nearly doubling in value.Guggenheim said that it liked Summit at $3 when the market was overlooking imminent data comparing progression-free survival with Summit’s Ivonescimab versus Merck's (MRK) blockbuster drug Pembrolizumab in lung cancer. Notably, the analyst said that they still like the stock at $24.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, &nbsp;while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_11_41_23_AM_png_000895180e.webp" alt="SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they see sustained growth potential for the stock.<stembedurl>https://stocktwits.com/db59/message/627464707</stembedurl>Guggenheim stated that if Summit's two late-stage clinical trials, HARMONi-3 and HARMONi-7, evaluating Ivonescimab in non-small cell lung cancer (NSCLC) are successful on progression-free survival or overall survival endpoints in 2027-2028, it has high conviction that the stock still has multi-fold upside potential from today's near-$20 billion valuation.While progression-free survival (PFS) is the length of time a patient with a disease, such as cancer, lives with the disease without it getting worse, or dies, overall survival (OS) is the total length of time a patient lives from the point of diagnosis or the start of treatment until death.HARMONi-3 is intended to evaluate Ivonescimab combined with chemotherapy compared to Pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is intended to evaluate Ivonescimab monotherapy compared to Pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors produce a high amount of the PD-L1 protein.SMMT stock is up 32% this year and approximately 96% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SMMT News

SMMT Summit Therapeutics Inc